SAB Biotherapeutics (SABS) Receivables (2020 - 2023)
SAB Biotherapeutics' (SABS) quarterly Receivables came in at $364117.0 in Q2 2023, down 96.21% YoY from $9.6 million in Q2 2022, and down 52.29% on a QoQ basis from $763123.0 in Q1 2023.
SAB Biotherapeutics (SABS) Receivables (2020 - 2023) Analysis & Trends
SAB Biotherapeutics (SABS) has 4 years of Receivables data on file, last reported at $364117.0 in Q2 2023.
- Quarterly Receivables fell 96.21% year-over-year to $364117.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $364117.0 (down 96.21% YoY) and the FY2022 annual result came in at $5.6 million, down 30.64% from the prior year.
- Receivables slipped to $364117.0 in Q2 2023, from $763123.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $20.6 million in Q4 2020 to a low of $364117.0 in Q2 2023.
- A 4-year average of $8.7 million and a median of $8.8 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables sank 30.64% — and 2023, when it tumbled 96.21%.
- Tracing SABS's Receivables over 4 years: stood at $20.6 million in 2020, then tumbled by 61.06% to $8.0 million in 2021, then slumped by 30.64% to $5.6 million in 2022, then tumbled by 93.45% to $364117.0 in 2023.
- The last three Receivables figures came in at $364117.0 (Q2 2023), $763123.0 (Q1 2023), and $5.6 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 364,117.00 |
| Mar 31, 2023 | 763,123.00 |
| Dec 31, 2022 | 5.56 Mn |
| Sep 30, 2022 | 12.90 Mn |
| Jun 30, 2022 | 9.61 Mn |
| Mar 31, 2022 | 11.79 Mn |
| Dec 31, 2021 | 8.01 Mn |
| Dec 31, 2020 | 20.57 Mn |